Systemic sclerosis complicated by arrhythmogenic right ventricular cardiomyopathy in a Chinese middle-aged female

References

• Desai CS, Lee DC, Shah SJ. Systemic sclerosis and the heart: current diagnosis and management. Curr Opin Rheumatol. 2011;23:545–554.
   PubMed Web of Science ®Google Scholar
• Kahan A, Coghlan G, McLaughlin V. Cardiac complications of systemic sclerosis. Rheumatology (Oxford). 2009;48(Suppl 3):iii45–iii48.
   PubMedGoogle Scholar
• Corrado D, Basso C, Thiene G, et al. Spectrum of clinicopathologic manifestations of arrhythmogenic right ventricular cardiomyopathy/dysplasia: a multicenter study. J Am Coll Cardiol. 1997;30:1512–1520.
   PubMed Web of Science ®Google Scholar
• Thiene G, Nava A, Corrado D, et al. Right ventricular cardiomyopathy and sudden death in young people. N Engl J Med. 1988;318:129–133.
   PubMed Web of Science ®Google Scholar
• Arai S, Kurasawa K, Maezawa R, et al. Systemic sclerosis complicated by arrhythmogenic right ventricular dysplasia that was misinterpreted as pulmonary arterial hypertension. Mod Rheumatol. 2012;22:152–157.
   PubMed Web of Science ®Google Scholar
• Dohi K, Nakamori S, Kurita T, et al. Arrhythmogenic right ventricular cardiomyopathy in a 20-year-old woman with systemic sclerosis. Intern Med. 2014;53:973–977.
   PubMed Web of Science ®Google Scholar
• Kallenberg CG, Wouda AA, Hoet MH, et al. Development of connective tissue disease in patients presenting with Raynaud’s phenomenon: a six year follow up with emphasis on the predictive value of antinuclear antibodies as detected by immunoblotting. Ann Rheum Dis. 1988;47:634–641.
   PubMed Web of Science ®Google Scholar
• Wollersheim H, Thien T, Hoet MH, et al. The diagnostic value of several immunological tests for anti-nuclear antibody in predicting the development of connective tissue disease in patients presenting with Raynaud’s phenomenon. Eur J Clin Invest. 1989;19:535–541.
   PubMed Web of Science ®Google Scholar
• Marcus FI, McKenna WJ, Sherrill D, et al. Diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia: proposed modification of the task force criteria. Euro Heart J. 2010;31:806–814.
   PubMed Web of Science ®Google Scholar
• Kant S, Holthöfer B, Magin TM, et al. Desmoglein 2-Dependent arrhythmogenic cardiomyopathy is caused by a loss of adhesive function. Circ Cardiovasc Genet. 2015;8:553–563.
   PubMedGoogle Scholar
• Basso C, Bauce B, Corrado D, et al. Pathophysiology of arrhythmogenic cardiomyopathy. Nat Rev Cardiol. 2011;9:223–233.
   PubMed Web of Science ®Google Scholar
• Garrod D, Chidgey M. Desmosome structure, composition and function. Biochim Biophys Acta. 2008;1778:572–587.
   PubMed Web of Science ®Google Scholar
• Baykan A, Olgar Ş, Argun M, et al. Different clinical presentations of Naxos disease and Carvajal syndrome: case series from a single tertiary center and review of the literature. Anatol J Cardiol. 2015;15:404–408.
   Web of Science ®Google Scholar
• Protonotarios N, Tsatsopoulou A. Naxos disease and Carvajal syndrome: cardiocutaneous disorders that highlight the pathogenesis and broaden the spectrum of arrhythmogenic right ventricular cardiomyopathy. Cardiovasc Pathol. 2004;13:185–194.
   PubMed Web of Science ®Google Scholar
• Rasmussen TB, Nissen PH, Palmfeldt J, et al. Truncating Plakophilin-2 Mutations in arrhythmogenic cardiomyopathy are associated with protein haploinsufficiency in both myocardium and epidermis. Circulation. 2014;7:230–240.
   Web of Science ®Google Scholar
• Ebert LM, Tan LY, Johan MZ, et al. A non-canonical role for desmoglein-2 in endothelial cells: implications for neoangiogenesis. Angiogenesis. 2016;19:463–486.
   PubMed Web of Science ®Google Scholar
• Giusti B, Fibbi G, Margheri F, et al. A model of anti-angiogenesis: differential transcriptosome profiling of microvascular endothelial cells from diffuse systemic sclerosis patients. Arthritis Res Ther. 2006;8:R115.
   Web of Science ®Google Scholar
• Giusti B, Margheri F, Rossi L, et al. Desmoglein-2-integrin Beta-8 interaction regulates actin assembly in endothelial cells: deregulation in systemic sclerosis. PLoS One. 2013;8:e68117.
   Web of Science ®Google Scholar
• Kavian N, Servettaz A, Mongaret C, et al. Targeting ADAM-17/notch signaling abrogates the development of systemic sclerosis in a murine model. Arthritis Rheum. 2010;62:3477–3487.
   PubMed Web of Science ®Google Scholar
• Wang H, Li ZY, Liu Y, et al. Desmoglein 2 is a receptor for adenovirus serotypes 3, 7, 11 and 14. Nat Med. 2011;17:96–104.
   PubMed Web of Science ®Google Scholar
• Wang H, Ducournau C, Saydaminova K, et al. Intracellular signaling and desmoglein 2 shedding triggered by human adenoviruses Ad3, Ad14, and Ad14P1. J Virol. 2015;89:10841–10859.
   Web of Science ®Google Scholar
• Awad MM, Calkins H, Judge DP. Mechanisms of disease: molecular genetics of arrhythmogenic right ventricular dysplasia/cardiomyopathy. Nat Clin Pract Cardiovasc Med. 2008;5:258–267.
   PubMedGoogle Scholar
• Ohno S, Nagaoka I, Fukuyama M, et al. Age-dependent clinical and genetic characteristics in Japanese patients with arrhythmogenic right ventricular cardiomyopathy/dysplasia. Circ J. 2013;77:1534–1542.
   Web of Science ®Google Scholar
• Sano M, Satoh H, Suwa K, et al. Characteristics and clinical relevance of late gadolinium enhancement in cardiac magnetic resonance in patients with systemic sclerosis. Heart Vessels. 2015;30:779–788.
   Web of Science ®Google Scholar
• Tandri H, Saranathan M, Rodriguez ER, et al. Noninvasive detection of myocardial fibrosis in arrhythmogenic right ventricular cardiomyopathy using delayed-enhancement magnetic resonance imaging. J Am Coll Cardiol. 2005;45:98–103.
   PubMed Web of Science ®Google Scholar
• Gaertner A, Klauke B, Stork I, et al. In vitro functional analyses of arrhythmogenic right ventricular cardiomyopathy-associated desmoglein-2-missense variations. PLoS One. 2012;7:e47097
   PubMed Web of Science ®Google Scholar